Mission
Harness the power of AI to revolutionize personalized medicine and drug development, improving clinical outcomes
Harness the power of AI to revolutionize personalized medicine and drug development, improving clinical outcomes
We have developed a one-of-a-kind phenotype atlas which has learned high level information from across all landscapes of cancer pathology, allowing us to quickly and efficiently deploy to new use cases in order to predict outcome, treatment response, and even genotype mutations.
Identifies the best cancer treatments for improved clinical outcomes.
Accelerates clinical trials and increases success rates with guided patient selection.
Provides a unique approach for quick identification of new biomarkers for precision medicine development.
“far reaching clinical implications”
“At present there is no biomarker that can predict triple negative breast cancer (TNBC) response to standard-of-care
“high accuracy”
“This is the first demonstration of using an AI tool on digitized H&E tissue images to predict response to NAC in patients with TNBC with high accuracy.” – Savitri Krishnamurthy, MD, Professor, Department of Pathology, MD Anderson Cancer Center